Agilent Posts 32 Percent Jump in Q2 Revenues, Strong LC and Mass Spec Sales | GenomeWeb

Agilent Technologies reported a 32 percent rise in its fiscal second-quarter revenues year over year, with its Life Sciences segment seeing a 39 percent jump driven, in part, by more than 20 percent growth in sales of its mass spectrometry and liquid chromatography platforms.

Life Science revenues were $464 million, up from $334 million in Q2 of last year. Overall, the company posted revenues of $1.68 billion for the quarter, up from $1.27 billion a year ago and beating analyst estimates of $1.6 billion.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: a global genetic interaction map for Saccharomyces cerevisiae, and progress made in genomics, precision medicine, and therapeutics.

The price of plane tickets can affect how scientists in different countries choose to collaborate with each other, NPR reports.

The Annals of Improbable Research has awarded the 2016 Ig Nobel Prizes.

Scientific American alleges that the FDA has been "arm-twisting journalists into relinquishing their reportorial independence."